home / stock / wint / wint news


WINT News and Press, Windtree Therapeutics Inc. From 10/25/22

Stock Information

Company Name: Windtree Therapeutics Inc.
Stock Symbol: WINT
Market: OTC
Website: windtreetx.com

Menu

WINT WINT Quote WINT Short WINT News WINT Articles WINT Message Board
Get WINT Alerts

News, Short Squeeze, Breakout and More Instantly...

WINT - Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent

WARRINGTON, Pa., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the United States Patent and Trademark Office (USPTO) has i...

WINT - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re taking a look at the biggest pre-market stock movers traders need to know about on Thursday morning! Moving stocks this morning are clinical trial results, public s...

WINT - What The Stock Market Did Today & Top Penny Stocks To Watch Now

What Did The Stock Market Do Today? – September 28, 2022 Edition If you were trading penny stocks or higher-priced names, you likely saw another active day of trading. Unlike yesterday’s bearish rout, the stock market today saw a surge in bullish buying. Some speculate...

WINT - Windtree Therapeutics Announces Positive Istaroxime Phase 2 Study in Early Cardiogenic Shock (SEISMiC) Published in the European Journal of Heart Failure

WARRINGTON, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that the results of its positive Phase 2 istaroxime study in ea...

WINT - Windtree Therapeutics Announces Istaroxime Late Breaker Abstract from its Positive Phase 2 Study in Early Cardiogenic Shock (SEISMiC) to be Presented at Heart Failure Society of America

WARRINGTON, Pa., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today reported that a late breaking abstract describing dose response data fro...

WINT - Windtree to Present at the Ladenburg Thalmann Healthcare Conference

WARRINGTON, Pa., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will...

WINT - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock We’re starting Wednesday with an overview of the biggest pre-market stock movers this morning! There’s an earnings report, an upcoming reverse stock split, and more to go over this...

WINT - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning! Moving stocks this morning is an acquisition deal, an update from ...

WINT - Windtree to Present at the H.C. Wainwright 24th Annual Global Investment Conference

WARRINGTON, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute cardiovascular disorders, today announced that Craig Fraser, President and Chief Executive Officer, will...

WINT - Week In Review: China And The U.S. May Settle De-Listing/Accounting Impasse

Summary According to a Wall Street Journal report, China and the US are close to solving the accounting rules crisis that threatens to de-list 261 China companies from US exchanges. Lee's Pharm of Hong Kong entered a $78.9 million deal with Windtree Therapeutics for global rights ...

Previous 10 Next 10